A question worth carrying
CJC-1295 needs its full chemical name
Three extra letters can change which research belongs with the name.
A folded paper passes across the library ledge.
DAC is part of the identity
CJC-1295 copies a shorter piece of growth hormone-releasing hormone, or GHRH, with some building blocks changed. It is meant to signal the pituitary gland beneath the brain to release growth hormone.
The version with DAC has an extra attachment. DAC stands for drug affinity complex; it binds to albumin, a common blood protein, and helps the peptide last longer. The version without it is different.
FDA’s review of the different forms separates two active ingredients, with and without DAC, across five chemical forms. The two active ingredients cannot be swapped, and the salt matters too. In that review, FDA found no human study of CJC-1295 without DAC. The published human work appears to have used the DAC form, without specifying the salt.
A sample needs its own answer
Researchers once identified CJC-1295 in an unknown pharmaceutical preparation. That answers a question about one sample. It doesn’t certify every other product carrying the name or tell us whether treatment helps.
The hormone response lasted
The early studies in healthy adults found a lasting rise in growth hormone and IGF-1, a related growth factor. That is the central finding worth keeping.
Those studies did not show better sleep, muscle growth or slower aging. A hormone can change without answering whether a person feels or functions better. There is no FDA-approved CJC-1295 medicine.
Longer does not mean better
It cannot rank CJC-1295 above sermorelin or tesamorelin. Their studies asked different questions in different people. The comparison puts those differences beside the shared pathway.
The safety concerns did not disappear
A withdrawn nomination is easy to misread. CJC-1295 appears under “nominated but withdrawn” on FDA’s safety page, dated April 22, 2026. That describes the compounding nomination, not a clearance. FDA gives no individual withdrawal date.
FDA still lists immune-reaction concerns and serious events associated with CJC-1295, including increased heart rate and reactions involving widening blood vessels. Those reactions can include flushing or a blood-pressure drop.
Keep the unknowns in the answer
FDA’s fuller review says long-term human safety is unknown. Withdrawal does not mean approval for compounding. That uncertainty belongs beside the hormone result whenever the finding gets passed along.